ContextLogic Inc. operates as a technology-driven company that focuses on enhancing the shopping experience for consumers by leveraging a unique platform
Its primary service is in the realm of e-commerce, where it connects buyers with a wide variety of products from numerous retailers through an intuitive interface. The company emphasizes personalized shopping experiences powered by data analytics and user engagement, aiming to simplify the purchasing process and provide value to both consumers and merchants. Through its innovative approach, ContextLogic fosters a dynamic online marketplace that promotes instant discovery and access to a diverse range of goods.
Under the deal, BC Partners planned to buy up to $150 million of convertible preferred units, a newly-formed Delaware limited liability company and a wholly-owned subsidiary of the company.
Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash
OAKLAND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and nine months ended September 30, 2024.
LogicBio Therapeutics's (NASDAQLOGC) short percent of float has fallen 62.5% since its last report. The company recently reported that it has 29 thousand shares sold short, which is 0.12% of all regular shares that are available for trading.
OAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and six months ended June 30, 2024.
BALA CYNWYD, Penn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC) to Alexion, AstraZeneca Rare Disease. Under the terms of the proposed transaction, shareholders of LogicBio will receive $2.07 for each share of LogicBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BALA CYNWYD, Pa., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC) to Alexion, AstraZeneca Rare Disease. Under the terms of the proposed transaction, shareholders of LogicBio will receive $2.07 for each share of LogicBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Gainers LogicBio Therapeutics, Inc. (NASDAQLOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
BALA CYNWYD, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Gainers LogicBio Therapeutics, Inc. (NASDAQLOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQLOGC) to AstraZeneca Rare Disease for $2.07 per share is fair to LogicBio shareholders.
Gainers LogicBio Therapeutics (NASDAQLOGC) shares moved upwards by 641.3% to $2.02 during Monday's pre-market session. The company's market cap stands at $66.5 million.
LogicBio Therapeutics Inc (NASDAQLOGC) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC NASDAQ: AZNNASDAQAZN)
